Horizon Pharma plc Announces Clinical Data to Be Presented at the 2015 ACR/ARHP Annual Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Guggenheim Shows Increasing Confidence in Horizon Pharma (HZNP) Following 3Q Beat; Reiterates Buy
November 6, 2015 11:10 AM ESTGuggenheim reiterated a Buy rating and $40.00 price target on Horizon Pharma (NASDAQ: HZNP) following the company's 3Q15 earnings report. HZNP reported adjusted diluted 3Q15 EPS of $0.70, $0.29 above consensus. The company also raised its '15 EBITDA guidance to $350MM-$360MM from $265MM-$280MM, consensus was... More
